TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates

Key Takeaways TMDX reported Q4 EPS of 57 cents, up 200% year over year, beating estimates by 39%.TransMedics posted 32% revenue growth in Q4, driven by the Organ Care System and logistics expansion.TMDX sees 2026 revenues of $727M-$757M, implying 20-25% growth over 2025 levels.TransMedics Group (TMDX) delivered earnings per share (EPS) of 57 cents in the fourth quarter of 2025, excluding a one-time benefit related to deferred tax assets, which surged 200% year over year. The figure surpassed the Zacks Conse ...